With rapid growth in trials, Chinese pharmaceutical companies are accelerating their transformation from producing generic drugs to developing innovative drugs

(Shanghai, October 27, 2021, PR Newswire news) - Informa Pharma Intelligence, a global medical think tank information platform, has recently released a white paper on the topic of "China's Clinical Trials"
.

As a key link in the development of innovative drugs, clinical trials of new drugs have developed rapidly under the impetus of policies, markets, and technologies in recent years, presenting a prosperous and multi-wheel drive scene

The author of this report, Andy Benson, Senior Director of Trialtrove®, and Dr.
Annie Siu, Director of Asia Pacific Content of Informa Pharma Intelligence, said: “In this study, we found that the average annual growth rate of clinical trials initiated in China from 2016 to 2020 was 20%.
Compared with the average annual growth rate of 12% during 2007‒2017, the increase in the number of initiated trials is also at the highest level in history
.

It can be seen that China is gradually becoming more Innovative drug research and development site

After a 5-year golden period, China's clinical trial market will continue to grow rapidly

After a 5-year golden period, China's clinical trial market will continue to grow rapidly

The period from 2016 to 2020 is the "five-year golden period" of the vigorous development of China's clinical trial market
.

As the National Medical Products Administration (NMPA) has successively promulgated a number of policies to deepen pharmaceutical reform and encourage innovation, supported by strong compliance supervision, drug clinical trial management practices, and continuously optimized data management methods, domestic pharmaceuticals The value excavated by companies from clinical trials is increasing year by year, which in turn promotes the rapid growth of China's clinical trial market

Informa Pharma Intelligence's "China Clinical Trial Pattern" white paper pointed out that since 2016, the number of clinical trials initiated in China has increased from 1,785 in 2016 to 3641 in 2020, with an average annual growth rate of about 20%, which is a relatively fast growth rate.

.

With favorable policy reforms, intensified competition and rising clinical demand, the domestic pharmaceutical industry has gradually shifted from the production of generic drugs and active pharmaceutical ingredients (API) to a high-tech-driven R&D model.

The report predicts that if the Chinese pharmaceutical market continues to develop in accordance with current trends, it will promote the in-depth supply and demand-side structural reforms of the Chinese clinical trial market, empower the deepening development of domestic clinical trial services and close cooperation with multinational pharmaceutical companies (MNC) , China’s share of global clinical trials is expected to increase further
.

With the rapid growth of trials, China's innovative drugs are gaining momentum

With the rapid growth of trials, China's innovative drugs are gaining momentum

Clinical trials in China are in a period of rapid growth, and bioequivalence (BE) research is an important factor driving the increase in the number of clinical trials
.

In the past five years, the number of BE trials has increased by more than three times.

The focus on innovative drugs in the Chinese pharmaceutical market has also spawned the prosperity of new drug clinical trials.
In the past five years, the overall growth of single phase I clinical trials has reached 136%, of which the number of trials sponsored by domestic companies has increased by 156%
.

This also implies that China's innovative drug power is rising at an alarming rate

Oncology drugs have always been regarded as the jewel in the crown of the pharmaceutical industry
.

The data of this survey shows that the number of tumor-related trials is still in the first place, several times the number of clinical studies in other treatment fields

Chinese pharmaceutical companies will continue to improve their international competitiveness

Chinese pharmaceutical companies will continue to improve their international competitiveness

Chinese pharmaceutical companies are accelerating their transformation from the production of generic drugs to the research and development of innovative drugs, and continue to improve their competitiveness in the international market
.

The white paper shows that in the past five years, eight of the top ten sponsors are Chinese pharmaceutical companies, which shows that Chinese pharmaceutical companies are paying more and more attention to clinical trials

With the mature technology development of domestic pharmaceutical companies and the support of abundant clinical data, the white paper predicts that in the future, more and more Chinese pharmaceutical companies will conduct international multi-center clinical trials (MRCT) on their own, or choose to conduct global cooperation with overseas partners.
Clinical trials
.
Informa Pharma Intelligence, as a global pharmaceutical industry consulting service organization, will also be an important partner of Chinese and international pharmaceutical companies
.